Mycobacterium Tuberculosis Market to Set $1,385.79 Mn by 2034

Mycobacterium Tuberculosis Market Size, Trends and Future Growth

The mycobacterium tuberculosis market was estimated at US$ 730.00 million in 2023 and is projected to grow to US$ 1,385.79 million by 2034, rising at a compound annual growth rate (CAGR) of 6% from 2024 to 2034. The increasing incidences of tuberculosis, advances in diagnostic assays, and increasing demand for novel treatments drive the market.

Unlock Infinite Advantages: Subscribe to Annual Membership

Mycobacterium Tuberculosis Market: Eradicating TB

Mycobacterium tuberculosis is a bacteria that causes tuberculosis (TB) in humans. TB is an infectious disease that infects the lungs or other tissues. Symptoms of TB include a long-lasting cough, pain in the chest, coughing up blood or sputum, fatigue or weakness, loss of appetite, and weight loss. TB is diagnosed using tuberculin skin tests, blood tests, sputum tests, X-rays, or CT scans. The common treatment drugs for TB include isoniazid, rifampin, ethambutol, pyrazinamide, and rifapentine. 

The increasing incidences of TB disease drive the market. TB is the second-leading infectious killer disease after COVID-19 globally. According to the WHO, approximately 10.6 million people globally were reported with TB in 2022, out of which 5.8 million were men, 3.5 million were women, and 1.3 million were children. Additionally, the advent of advanced detection techniques for TB and growing research and development augment the market growth. The rise in multi-drug resistant TB (MDR TB) increases the demand for novel drug discovery, potentiating the market.

Mycobacterium Tuberculosis Market Trends

• In September 2024, the UKRI cross-research council responsive mode (CRCRM) pilot scheme awarded funding of nearly £1.2 million to researchers from Cardiff Aberystwyth universities for the development of novel point-of-care mycobacterium tuberculosis detection within 1 hour.
• In July 2024, the National Institute of Health’s National Institute of Allergy and Infectious Diseases awarded a five-year grant of $31 million to a consortium to accelerate the development of faster, more effective treatment regimens for TB. The consortium comprises investigators from the University of California, Johns Hopkins Medicine, and Vanderbilt University Medical Center.
• The new WHO guidelines of 2022 prioritized a 6-month regimen – the BPaLM/BPaL – as a treatment of choice for eligible drug-resistant patients. BPaL includes bedaquiline, pretomanid, and linezolid and BPaLM includes BPaL + Moxifloxacin. The study found that this treatment regimen is more effective, shorter, less burdensome for patients, cheaper, and saves more lives.

Innovative Diagnostics: Opportunity for the Market

The increasing incidences of tuberculosis and deaths have led to the development of early detection and efficient treatment regimens. Several government bodies and private organizations are investing in supporting TB research. The advancements in technology and biotechnology research demonstrate innovations in TB diagnosis. The demand for rapid and accurate detection promotes innovations in diagnostic testing. Novel testing methods such as nucleic acid amplification tests (NAAT) and line probe assays (LPA) are based on PCR techniques. Researchers have also developed novel methods based on gene editing techniques like CRISPR-Cas9 to identify the genes of mycobacterium tuberculosis bacteria. Additionally, advanced technologies like artificial intelligence drive automation in the detection. Computer-aided detection for chest radiographs uses AI to improve sensitivity and specificity.

Lack of Treatment Access in Rural Areas Hinder the Market Growth

Patients in rural areas of many countries, especially in lower- and middle-income countries, find it difficult to access high-quality healthcare services. This limits the early detection of TB, thereby hampering efficient treatment of the patients, resulting in slow and insufficient case detection and low cure rates. Additionally, the huge treatment costs limit the affordability of poor people. The treatment cost depends on the severity of the disease, and it ranges from $20,000 to $200,000 annually in the U.S.

Government TB Programs Dominated the North American Market

North America dominated the mycobacterium tuberculosis market in 2023. The state-of-the-art research and development facilities, increasing incidences of TB, and increasing investments drive the market. There were around 8,331 TB cases in the US and 1,971 TB cases in Canada in 2022. The U.S. reported a 5.9% increase in cases from 2021. The US and the Canadian governments regularly release guidelines on eradicating TB in the region. Each US state has its own TB program. The Division of Tuberculosis Elimination by the CDC funds four Tuberculosis Centers of Excellence for Training, Education, and Medical Consultation for the project period of 2023-2027. The market is also driven by technological advancements and the increasing number of clinical trials. The US is the largest donor to the Global Fund to Fight AIDS, TB, and Malaria. The US funding for 2023 was around $406 million.

Rising Incidences of TB Drives Asia-Pacific Market

Asia-Pacific is anticipated to grow fastest during the forecast period. The rising geriatric population, increasing incidences of TB, and growing research and development activities drive the mycobacterium tuberculosis market. In Japan, around 10,235 cases of TB were reported in 2022. Meanwhile, in South Korea, 20,383 TB cases were reported in 2022. Several government and private programs to eradicate TB also augment the market growth. Programs like the “5-year National TB Control Program” and the “National Tuberculosis Elimination Program” by the China and India Governments promote control and prevention of TB in the nation. Also, the Japan Anti-Tuberculosis Association aims to conduct activities related to the prevention and care of TB and spread awareness regarding the same. In 2022, the Indian Council of Medical Research (ICMR) was the fifth-largest funder of TB research, with an investment of $20 million.

Segmental Insights

By type, the molecular rapid diagnosis segment led the mycobacterium tuberculosis market in 2023. The demand for point-of-care diagnostics boosts the segment growth. Molecular rapid diagnosis has high diagnostic accuracy for detecting TB and MDR TB. The segment is also attributed to the recommendation by the WHO.

By type, the culture method is projected to grow significantly in the market over the coming years. The culture method is widely used during treatment monitoring and is the most sensitive and specific phenotypic method for detecting mycobacterium tuberculosis.

By application, the hospital segment held a dominant presence in the mycobacterium tuberculosis market. Hospitals are highly preferred as they possess specialized equipment for diagnosis and necessary treatment regimens depending on the patient’s condition. Hospitals have favorable infrastructure and trained professionals to treat the patients. Additionally, favorable reimbursement policies promote segment growth.

By Application, the clinics segment is expected to grow rapidly in the market during the forecast period. Clinics are preferred for the diagnosis and treatment of the initial stages of TB. Easy access and less expensive facilities make it a suitable choice.

Recent Developments in the Mycobacterium Tuberculosis Market

• In October 2024, researchers from the Shanghai Institute of Materia Medica, China, and McGill University, Canada, developed a novel modified sanguinarine, a natural compound, BPD-9, for the treatment of MDR TB.
• In August 2024, ICMR developed a novel and affordable CRISPR Cas-based TB detection system and plans to commercialize it. The system can test 1,500 samples in a short period, overcoming the limitations of the existing methods.

Top Companies in the Mycobacterium Tuberculosis Market

• Abbott Laboratories
• GlaxoSmithKline
• Janssen Pharmaceuticals
• Johnson & Johnson
• Lupin
• Macleods Pharmaceuticals Ltd.
• Mcneil & Argus Pharmaceuticals Ltd.
• Otsuka Pharmaceutical
• Roche Diagnostics
• Sequella, Inc.
• Thermo Fisher Scientific, Inc.

Segments Covered in the Report

By Type

• Smear Method
• Culture Method
• Molecular Rapid Diagnosis
• Others

By Application

• Hospital
• Clinic
• Others

By Region

• North America
  • US
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Thailand
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait